According to Foresight News, Nasdaq-listed Artelo Biosciences announced a public offering of 640,924 shares of common stock at a price of $4.40 per share, raising approximately $3 million.
Previously, Artelo Biosciences completed an $9.475 million private placement financing to initiate a digital asset reserve strategy centered around Solana (SOL), becoming the first publicly traded pharmaceutical company to include SOL as a reserve asset.
